Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TLL 018

Drug Profile

TLL 018

Alternative Names: TLL-018

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TLL Pharmaceutical
  • Developer Hangzhou Highlightll Pharmaceutical; TLL Pharmaceutical
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic urticaria; Rheumatoid arthritis
  • Phase II Plaque psoriasis; Ulcerative colitis
  • Phase I Atopic dermatitis

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Chronic-urticaria in China (PO, Tablet)
  • 10 Mar 2025 Hangzhou Highlightll Pharmaceutical initiates enrollment in a phase-III Long-term Extension trials in Rheumatoid arthritis (Treatment-experienced) in China (PO) (NCT06887127)
  • 24 Dec 2024 Phase-III clinical trials in Chronic-urticaria (Treatment-experienced) in China (PO, Tablet) (NCT06396026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top